Patient Access & Affordability
  • About
    • Mission
    • Team
    • Professional Advisory Council
    • Patient Advisors
    • Members
    • Funding
    • Contact
  • Resources
    • Blog
    • Watch & Listen
    • Surveys
  • Publications
    • Research Briefings
    • Current Issues
    • Fast Facts
    • Policy Platform
  • Working Groups
    • Benefit Design
    • Rare Disease Health Technology Assessment
    • Biosimilars & Complex Generics
  • ICERWATCH
    • What is ICER?
    • ICER Glossary
    • Analysis and Commentary
    • Public Comments
Select Page
ICER’s Latest: A draft evidence report on medications for obesity management

ICER’s Latest: A draft evidence report on medications for obesity management

by Editor | Jul 25, 2022 | Blog

On July 13, 2022 2021, ICER released its draft evidence report, “Medications for Obesity Management.” This is the first step in ICER’s process that is expected to conclude with the release of a final report in October 2022. ICER’s report reviews four medicines...

read more
ICER’s Latest: Draft Evidence Report on New ALS Treatments

ICER’s Latest: Draft Evidence Report on New ALS Treatments

by Editor | Jun 24, 2022 | Blog

On June 14, 2022, ICER released its draft evidence report, “AMX0035 and Oral Edaravone for Amyotrophic Lateral Sclerosis.” This is the first step in ICER's review process. A final evidence report is expected to be released in mid-September. Background on ALS...

read more
FTC Investigating Pharmacy Benefit Managers for Practices Impacting Patient Access

FTC Investigating Pharmacy Benefit Managers for Practices Impacting Patient Access

by Editor | Jun 22, 2022 | Blog

Earlier this month, the Federal Trade Commission (FTC) announced that it had launched a new inquiry into business practices of pharmacy benefit managers (PBMs). Specifically, the the five-member commission said that it would "scrutinize the impact of vertically...

read more
New Study: FDA consistently approves cancer treatments faster than its counterparts in Europe

New Study: FDA consistently approves cancer treatments faster than its counterparts in Europe

by Editor | Jun 17, 2022 | Blog

Over the past decade, the Food and Drug Administration (FDA) has significantly outpaced the European Medicines Agency (EMA) in approving new cancer treatments. This is according to a recent study published in JAMA Network Open. The study included a cross-sectional...

read more
Recommended Reading: Why So Slow? Legislators Take on Insurers’ Delays in Approving Prescribed Treatments

Recommended Reading: Why So Slow? Legislators Take on Insurers’ Delays in Approving Prescribed Treatments

by Editor | May 17, 2022 | Blog

Andrew Bade, who was diagnosed with Type 1 diabetes nearly two decades ago, is accustomed to all the medical gear he needs to keep his blood sugar under control. His insulin pump contains a disposable insulin cartridge, and a plastic tubing system with an adhesive...

read more
ICER’s Latest: A draft evidence report on new treatment for Beta Thalassemia

ICER’s Latest: A draft evidence report on new treatment for Beta Thalassemia

by Editor | Apr 27, 2022 | Blog

On April 13, 2022, ICER released its draft evidence report, “Betibeglogene Autotemcel for Beta Thalassemia.” This is the first step in ICER’s review process; ICER is scheduled to release a final report on this treatment in July 2022. Beta thalassemia is a disease...

read more
Businesses With High-Value, Low-Cost Health Insurance Receive First-Ever Health Plan Hero Awards

Businesses With High-Value, Low-Cost Health Insurance Receive First-Ever Health Plan Hero Awards

by Editor | Apr 21, 2022 | Blog

Six small businesses from across the country were among the first companies ever to receive a national award for their innovative, outstanding employer-sponsored health program. The companies received the 2022 Health Plan Hero award in a ceremony recently held in the...

read more
More of the Same: ICER’s latest salvo on rare diseases

More of the Same: ICER’s latest salvo on rare diseases

by Editor | Apr 20, 2022 | Blog

Earlier this month, ICER released a white paper titled “The Next Generation of Rare Disease Drug Policy: Ensuring Both Innovation and Affordability.” If you have been monitoring ICER’s work over the years, the paper likely matches your expectations. Ostensibly, the...

read more
Event: Health Plan Heroes Awards Program and Roundtable

Event: Health Plan Heroes Awards Program and Roundtable

by Editor | Mar 27, 2022 | Blog

Patients Rising's first annual Health Plan Heroes event will honor companies that have adopted innovative benefit design for their employees. In addition, a panel of experts will have a roundtable discussion on ways for employers to enhance patient access to care as...

read more
Last Word: ICER’s Premature Assessment of New Treatment for Type 2 Diabetes

Last Word: ICER’s Premature Assessment of New Treatment for Type 2 Diabetes

by Editor | Mar 16, 2022 | Blog

In mid-February, ICER released a Final Evidence Report on tirzepatide, a new insulin treatment for Type 2 diabetes (T2D). After following its normal process - including preliminary drafts and public comments - ICER concluded the new medication works better than the...

read more
« Older Entries

IPAA

700 12th St. NW, Suite 700
Washington, DC 20005
202-750-1186 |  info@accessandaffordability.org

The Patient Access & Affordability Project is a program of Patients Rising, a national 501(c)3 nonprofit organization, and is governed by the Patients Rising Board of Directors.

  • Facebook
  • Twitter
  • RSS